Gavin Wood and Christian Eberle join Atlas Antibodies’ Board of Directors
We are delighted to announce Gavin Wood and Christian Eberle as additions to our Board of Directors, elected by the AGM as of May 31 2023.
Åsa Riisberg was re-elected as Chair of the Board and Mathias Uhlen, Lotta Ljungqvist and Louise Kores were re-elected as Board members.
Gavin Wood and Christian Eberle
“It is with great pleasure that we are able to welcome our newest board members Gavin Wood and Christian Eberle. With their talent and long experience from the life sciences industry, I am convinced that both Gavin and Christian will be invaluable additions to Atlas Antibodies’ Board of Directors and support the company in our exciting growth journey ahead”, says Åsa Riisberg, Chair, Atlas Antibodies.
Gavin Wood, currently the Chief Financial Officer of Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a leader in TCR T-cell therapy, has over 17 years of experience from senior roles within the life sciences sector, focusing on financial operations and strategy. Prior to joining Adaptimmune, Gavin served as the Chief Financial Officer at Abcam Plc (LSE:ABC) and Executive Vice President and Chief Financial Officer at Affymetrix Inc. (NASDAQ:AFFX).
“Atlas Antibodies is a life sciences company with a clear vision and unique heritage. I am delighted to have been appointed to the Atlas Antibodies board and look forward to taking up my role”, says Gavin Wood.
Dr. Christian Eberle comes most recently from the role as CEO of evitria, part of the Atlas Antibodes group. During his career, Christian Eberle has accumulated broad experience in business strategy as well as in research, development and manufacturing within the pharmaceutical and biotechnology industry, including CDMO companies.
“It has been a pleasure and privilege to lead evitria as a CEO for over three years and I am very pleased to continue my involvement with Atlas Antibodies in capacity as Board member”, says Christian Eberle.